RxDoctor Payments DataLook up a doctor →

Eric Batts, MD

Hematology & Oncology · Holland, MINPI 1821126830

Payments from drug & device makers

$1,645,208in general payments, 2019–2025

Across 460 payments — averaging $3576.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1M
  • Merck$249K
  • Seagen Inc.$173K
  • Pfizer$113K
  • AbbVie$53K
  • Daiichi Sankyo Inc.$30K
  • plus $6K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca52$1,022,520
Merck23$249,268
Seagen Inc.30$172,509
Pfizer35$112,651
AbbVie15$52,727
Daiichi Sankyo Inc.19$29,550
Novartis33$592
Genentech USA, Inc.24$407
Takeda Pharmaceuticals U.S.A., Inc.16$405
Eisai Inc.20$376
Gilead(2 entities)13$272
Johnson & Johnson14$270
Astellas Pharma US Inc12$269
GSK12$234
Pharmacyclics LLC, An Abbvie Company11$230
Jazz Pharmaceuticals Inc.7$172
Incyte Corporation9$166
Bristol Myers Squibb8$147
Exelixis Inc.6$146
Lilly USA, LLC6$120
Foundation Medicine, Inc.1$112
Sanofi5$108
Tersera Therapeutics LLC5$108
Array Biopharma Inc5$105
E.r. Squibb & Sons, L.L.C.6$104
EMD Serono, Inc.6$100
Telix Pharmaceuticals1$100
Beigene USA, Inc.4$98
Astrazeneca UK Limited2$95
Regeneron Healthcare Solutions, Inc.4$94
Bayer3$78
Kyowa Kirin, Inc.4$73
Mirati Therapeutics, Inc.4$69
Ipsen Biopharmaceuticals, Inc3$66
Puma Biotechnology, Inc.4$66
Servier Pharmaceuticals LLC3$63
Karyopharm Therapeutics Inc.3$57
Amgen3$56
Sumitomo Pharma America, Inc.3$53
Progenics Pharmaceuticals, Inc.2$51
Taiho Oncology, Inc.2$43
ADC Therapeutics America, Inc.2$43
Stemline Therapeutics Inc.2$43
Rigel Pharmaceuticals, Inc.2$40
Agios Pharmaceuticals, Inc.1$35
Springworks Therapeutics, Inc.2$34
Sun Pharmaceutical Industries Inc.1$30
Boehringer Ingelheim1$30
Amneal Pharmaceuticals LLC1$29
Geron Corporation1$27
Myovant Sciences Inc.1$24
Beone Medicines USA, Inc.1$24
Sobi, Inc1$23
Pharmaessentia USA Corporation1$19
Acrotech Biopharma Inc.1$19
Deciphera Pharmaceuticals Inc.1$17
AVEO Pharmaceuticals, Inc.1$15
Caris MPI, Inc.1$15
CTI Biopharma Corp.1$14

How this compares

$1,645,208 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan →

Medicare billing

Part B allowed, 2024
$2,680,786
Medicare patients
436
Services billed
126,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Holland

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →